Status:

COMPLETED

Explanatory Clinical Trial of a Novel Parent Intervention for Childhood Anxiety (SPACE)

Lead Sponsor:

Yale University

Collaborating Sponsors:

National Institute of Mental Health (NIMH)

Conditions:

Anxiety Disorders

Anxiety, Separation

Eligibility:

All Genders

7-14 years

Phase:

NA

Brief Summary

Childhood anxiety disorders are very common, carry tremendous personal and societal costs, frequently do not respond adequately to treatment, and involving parents in treatment has so far not enhanced...

Detailed Description

Despite strong evidence for the efficacy of individual cognitive-behavior therapy (ICBT) for childhood anxiety disorders, up to 50% of children remain symptomatic after treatment and many still meet d...

Eligibility Criteria

Inclusion

  • Children:
  • meet criteria for a primary DSM5 anxiety disorder of generalized anxiety disorder (GAD), social phobia (SOP), and separation anxiety disorder (SAD) using the DSM-5 version of the Anxiety Disorders Interview Schedule -Child and Parent Versions (ADIS-C/P)
  • mean score of 4 or greater on the ADIS-C/P Clinician Rating Scale of Severity (CSR)
  • ceasing all other psychosocial treatment upon consultation with the clinic staff and the service provider
  • not using any psychotropic medication other than a stable dose of stimulant medication treatment for comorbid ADHD or a stable dose of Selective Serotonin Reuptake Inhibitor (SSRI)
  • children who are on a stable dose of stimulant medication or SSRI (i.e., a minimum of six weeks at the same dose) will be included so as not to limit generalizability.

Exclusion

  • Children:
  • primary diagnosis of any Axis I DSM-IV disorder other than GAD, SOP, Phobias and SAD
  • any of the following disorders (e.g., primary, secondary, tertiary) - Pervasive Developmental Disorders, Mental Retardation, Organic Mental Disorders, Bipolar Disorder, Schizophrenia and Other Psychotic Disorders
  • drug or alcohol abuse/dependence will also be exclusionary
  • tic disorders will not be exclusionary unless they require psychotropic medication to stabilize
  • Significant active suicidal ideation or a past suicide attempt in the last 6 months. Adolescents with a history of non-lethal self-harm behaviors (e.g., cutting) will be allowed to enroll if they meet other criteria
  • have an intellectual disability as reported by guardian
  • be a victim of past or present undisclosed abuse requiring investigation or ongoing supervision by the Department of Social Services
  • not have been cohabiting with mother for at least one year prior to admittance. Parent:
  • any of the following disorders (e.g., primary, secondary, tertiary) - Pervasive Developmental Disorders, Mental Retardation, Selective Mutism, Organic Mental Disorders, Bipolar Disorder, Schizophrenia and Other Psychotic Disorders. Drug or alcohol abuse/dependence will also be exclusionary
  • not have been cohabiting with child for at least one year prior to admittance
  • report the presence of any active suicidal ideation or a past suicide attempt in the last 6 months.

Key Trial Info

Start Date :

November 1 2014

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 1 2018

Estimated Enrollment :

124 Patients enrolled

Trial Details

Trial ID

NCT02310152

Start Date

November 1 2014

End Date

November 1 2018

Last Update

March 9 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Yale University Child Study Center

New Haven, Connecticut, United States, 06519